MA40386A - Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci - Google Patents

Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci

Info

Publication number
MA40386A
MA40386A MA040386A MA40386A MA40386A MA 40386 A MA40386 A MA 40386A MA 040386 A MA040386 A MA 040386A MA 40386 A MA40386 A MA 40386A MA 40386 A MA40386 A MA 40386A
Authority
MA
Morocco
Prior art keywords
analogs
cabozantinib
preparing fluorine
labeled
preparing
Prior art date
Application number
MA040386A
Other languages
English (en)
Inventor
Patrick L Chow
David J Donnelly
Benjamin J Henley
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA40386A publication Critical patent/MA40386A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un procédé de préparation de cabozantinib ([4- (6,7-diméthoxy-quinolin-4-yloxy)phénylo]amide-(4-fluoro-phényl)amide) d'acide cyclopropane-1,1-dicarboxylique) et de cabozantinib marqué au
MA040386A 2014-07-31 2015-07-31 Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci MA40386A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462031471P 2014-07-31 2014-07-31

Publications (1)

Publication Number Publication Date
MA40386A true MA40386A (fr) 2016-02-04

Family

ID=54072944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040386A MA40386A (fr) 2014-07-31 2015-07-31 Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci

Country Status (9)

Country Link
US (2) US11124481B2 (fr)
EP (1) EP3174854B1 (fr)
JP (2) JP6789923B2 (fr)
CN (1) CN106715397B (fr)
CA (1) CA2956810C (fr)
EA (1) EA033834B1 (fr)
ES (1) ES2929888T3 (fr)
MA (1) MA40386A (fr)
WO (1) WO2016019285A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119321C2 (uk) 2013-03-15 2019-06-10 Екселіксіс, Інк. Метаболіти n-(4-{[6,7-біс(метилокси)хінолін-4-іл]окси}феніл)-n'-(4-фторфеніл)циклопропан-1,1-дикарбоксаміду
CA3181899A1 (fr) 2014-02-14 2015-08-20 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, procedes de preparation, et methodes d'utilisation
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
WO2016019285A1 (fr) * 2014-07-31 2016-02-04 Exelixis, Inc. Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
CA2957466C (fr) 2014-08-05 2023-10-17 Exelixis, Inc. Combinaison de medicaments pour traiter le myelome multiple
CA3020749A1 (fr) 2016-04-15 2017-10-19 Exelixis, Inc. Procede de traitement du cancer a cellules renales a l'aide de n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107556238A (zh) * 2016-06-30 2018-01-09 深圳万乐药业有限公司 一种卡博替尼的合成方法
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning
WO2018227119A1 (fr) 2017-06-09 2018-12-13 Exelixis, Inc. Formes galéniques liquides destinées à traiter le cancer
CN109836381A (zh) * 2017-11-29 2019-06-04 连云港恒运药业有限公司 多受体酪氨酸激酶抑制剂及其中间体的制备方法
CN109988107B (zh) * 2017-12-29 2022-01-14 江苏豪森药业集团有限公司 卡博替尼的制备方法
IL300824A (en) 2018-01-26 2023-04-01 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN111440119B (zh) * 2019-07-09 2021-08-24 郑州大学第一附属医院 卡博替尼中间体的制备方法
CN110903240A (zh) * 2019-12-12 2020-03-24 上海玉函化工有限公司 一种广谱抗癌药卡博替尼的制备方法
TW202346255A (zh) * 2022-01-06 2023-12-01 日商中外製藥股份有限公司 醯胺化合物的製造方法
WO2024114710A1 (fr) * 2022-12-01 2024-06-06 江苏奥赛康药业有限公司 Procédé de préparation de cabozantinib et d'un intermédiaire de celui-ci
WO2024163400A1 (fr) * 2023-01-31 2024-08-08 Handa Oncology, Llc Compositions de cabozantinib améliorées et procédés d'utilisation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260221A1 (en) * 2000-04-03 2001-10-15 Abb Ab A multiphase induction device
EP2612853A1 (fr) 2003-09-26 2013-07-10 Exelixis Inc. Modulateurs c-Met et produits d'utilisation
WO2006014325A2 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
JP2007056777A (ja) 2005-08-25 2007-03-08 Daido Steel Co Ltd 電磁駆動弁
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
WO2008076415A1 (fr) 2006-12-14 2008-06-26 Exelixis, Inc. Procédés d'utilisation d'inhibiteurs de mek
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
TW201035017A (en) 2008-09-26 2010-10-01 Smithkline Beecham Corp Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
EA019247B1 (ru) 2008-11-13 2014-02-28 Экселиксис, Инк. Способы получения хинолиновых производных
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス， インコーポレイテッド キノリン誘導体の調製方法
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
EP2454238A1 (fr) 2009-07-17 2012-05-23 Exelixis, Inc. Formes cristallines du n [3 fluoro-4-({méthyloxy)-7-[(3-morpholin-4-yl- propyl)oxy]quinoléin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011112896A1 (fr) 2010-03-12 2011-09-15 Exelixis, Inc Forme cristaline hydratée du n-[3-fluoro-4-({6-(méthyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
PL2593090T3 (pl) 2010-07-16 2022-02-21 Exelixis, Inc. Kompozycje farmaceutyczne modulatora c-Met
EP2593091A1 (fr) 2010-07-16 2013-05-22 Exelixis, Inc. Compositions pharmaceutiques modulatrices de c-met
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012044577A1 (fr) 2010-09-27 2012-04-05 Exelixis, Inc. Doubles inhibiteurs de met et vegf pour le traitement du cancer de la prostate résistant à la castration et des métastases osseuses ostéoblastiques
ES2754973T5 (es) 2010-09-27 2023-03-13 Exelixis Inc Inhibidores duales de MET y VEGF para el tratamiento del cáncer de próstata resistente a la castración y metástasis óseas osteoblásticas
CN103327979A (zh) 2010-11-22 2013-09-25 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗癌症的方法
KR20210147117A (ko) 2011-02-10 2021-12-06 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EP2758057B1 (fr) * 2011-09-22 2017-05-31 Exelixis, Inc. Méthode de traitement de l'ostéoporose
BR112014009302B1 (pt) 2011-10-20 2020-04-28 Exelis Inc Us/Us processo para preparar derivados de quinolina
TW201818937A (zh) 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
UA119321C2 (uk) * 2013-03-15 2019-06-10 Екселіксіс, Інк. Метаболіти n-(4-{[6,7-біс(метилокси)хінолін-4-іл]окси}феніл)-n'-(4-фторфеніл)циклопропан-1,1-дикарбоксаміду
ES2927651T3 (es) * 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
JP2016515628A (ja) 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
CA3181899A1 (fr) 2014-02-14 2015-08-20 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, procedes de preparation, et methodes d'utilisation
JP6666849B2 (ja) * 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
PL3134084T3 (pl) 2014-04-25 2021-09-27 Exelixis, Inc. Sposób leczenia gruczolakoraka płuca
WO2016019285A1 (fr) * 2014-07-31 2016-02-04 Exelixis, Inc. Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
CA2957466C (fr) 2014-08-05 2023-10-17 Exelixis, Inc. Combinaison de medicaments pour traiter le myelome multiple
WO2016061253A1 (fr) 2014-10-14 2016-04-21 Exelixis, Inc. Combinaison de médicaments pour le traitement du mélanome
US10501415B2 (en) 2015-04-07 2019-12-10 Unitika Ltd. Method for producing bisimide dicarboxylic acid
AU2018210397B2 (en) 2017-01-20 2024-02-29 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Also Published As

Publication number Publication date
EP3174854A1 (fr) 2017-06-07
ES2929888T3 (es) 2022-12-02
US11124481B2 (en) 2021-09-21
EP3174854B1 (fr) 2022-08-24
JP2017523195A (ja) 2017-08-17
CN106715397B (zh) 2021-07-23
CA2956810A1 (fr) 2016-02-04
WO2016019285A1 (fr) 2016-02-04
JP6789923B2 (ja) 2020-11-25
US20220194902A1 (en) 2022-06-23
JP2020186261A (ja) 2020-11-19
EA201790286A1 (ru) 2017-06-30
US20170217896A1 (en) 2017-08-03
CN106715397A (zh) 2017-05-24
EA033834B1 (ru) 2019-11-29
CA2956810C (fr) 2022-10-04

Similar Documents

Publication Publication Date Title
MA40386A (fr) Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
IN2014CH00247A (fr)
PT3142785T (pt) Processo para a produção de alcenóis e sua utilização para a produção de 1,3-butadieno
WO2014125506A3 (fr) Procédé de préparation d'ivacaftor et de ses intermédiaires
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
PH12016502229A1 (en) Process for preparing phosphorus-containing cyanohydrins
IN2013MU00848A (fr)
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
MA40378A (fr) Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine
EP3265083A4 (fr) Analogues de depsipeptide d'urée substitués à utiliser en tant qu'activateurs de l'endopeptidase clpp
IN2013CH04906A (fr)
EP3506922A4 (fr) Analogues de depsipeptide d'urée substitués à utiliser en tant qu'activateurs de l'endopeptidase clpp
EP3122342A4 (fr) Procédé pour la préparation d'un amide de n-acétylcystéine
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
ZA201803105B (en) Industrial process for the preparation of (5s,10s)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (e)-3-carboxyacrylate salt
EP3130593A4 (fr) Dérivé d'acide phosphonique de phénanthroline et son procédé de préparation et d'utilisation
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MA40444A (fr) Procédé de préparation de formulations de poudre sèche
GEP20196944B (en) Process for preparing the inhalation formulations
EP3177592A4 (fr) Procédé de préparation d'acide 4,5,6-trichloropicolinique
IN2013CH05865A (fr)
MA40443A (fr) Nouveau procédé de préparation de formulations de poudre sèche
PT3365327T (pt) Processo para a preparação de fexofenadina e de intermediários usados no mesmo